Andrew Gengos

Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA.

Neuraltus Pharmaceuticals, Inc. develops and commercializes molecule therapeutics. It engages in the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death. The company was founded by Michael McGrath, Edgar G. Engleman, and Ari Azhir in 2004 and is headquartered in San Bruno, CA.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation.